Compare LPCN & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPCN | QNCX |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.1M | 19.9M |
| IPO Year | 2011 | 2019 |
| Metric | LPCN | QNCX |
|---|---|---|
| Price | $2.21 | $1.02 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 92.9K | ★ 1.4M |
| Earning Date | 05-07-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.18 | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | ★ $1,976,677.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $92.00 | N/A |
| P/E Ratio | ★ N/A | $0.36 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.81 | $0.08 |
| 52 Week High | $12.37 | $4.55 |
| Indicator | LPCN | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 33.70 | 44.90 |
| Support Level | $2.16 | $0.79 |
| Resistance Level | $2.50 | $1.45 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 36.54 | 42.80 |
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.